Clinical Trials Logo

Diabetic Nephropathy clinical trials

View clinical trials related to Diabetic Nephropathy.

Filter by:

NCT ID: NCT00044148 Completed - Clinical trials for Diabetic Nephropathy

The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

Start date: July 16, 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.

NCT ID: NCT00024921 Completed - Clinical trials for Diabetic Nephropathy

The Genetics of Kidneys in Diabetes (GoKinD) Study

Start date: n/a
Phase: N/A
Study type: Observational

Kidney disease in diabetes (diabetic nephropathy) tends to run in families. It is likely, therefore, that there are genes that predict or are associated with either getting or not getting diabetic nephropathy. The GoKinD Study will provide clinical information and DNA for investigators to look for these genes. Evaluation will be performed and DNA obtained from approximately 1100 diabetic persons with kidney disease and 1000 diabetic persons without kidney disease. In some cases, samples for DNA will also be obtained from the parents of these subjects. Clinical information and DNA will be coded so that individuals cannot be identified, but the DNA can be linked to the clinical data from the individual. Multiple investigators will be able to use this genetic material to test hypotheses about the genetics of kidney disease in diabetes.

NCT ID: NCT00004266 Completed - Clinical trials for Diabetic Nephropathy

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

Start date: August 1993
Phase: Phase 3
Study type: Interventional

OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.